Product image of Miglustat Dipharma (Miglustat) supplied by GNH India

Miglustat Dipharma

Active Ingredient:
Miglustat
Origin:
EU

Miglustat Dipharma (Miglustat)

Miglustat, the active ingredient in Miglustat Dipharma, is a glucosylceramide synthase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of Gaucher disease type 1 and Niemann‑Pick disease type C in patients requiring disease‑modifying therapy.

GNH India supplies Miglustat Dipharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, ensuring quality, regulatory compliance and reliable delivery across global markets, and our supply chain adheres to stringent GMP standards, providing comprehensive documentation to support import and clinical use.

Manufacturer / TM Owner

Waymade B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Miglustat is used as substrate reduction therapy for lysosomal storage disorders, targeting the accumulation of glycosphingolipids.

  • Gaucher disease type 1: reduces spleen and liver volume, improves hematologic parameters and bone disease.
  • Niemann‑Pick disease type C: stabilizes neurological progression and may improve quality of life.
  • Substrate reduction therapy: provides an oral option to manage glycosphingolipid buildup in selected lysosomal storage disorders.

How It Works

  • Miglustat selectively inhibits glucosylceramide synthase, the enzyme responsible for the first step in glycosphingolipid biosynthesis. By blocking this pathway, the drug decreases the production of glucosylceramide and downstream glycosphingolipids, reducing substrate accumulation within lysosomes. This substrate reduction approach complements enzyme replacement strategies and helps mitigate the pathological effects of lysosomal storage disorders.

Side Effects

Miglustat may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Diarrhea
  • Nausea
  • Abdominal pain
  • Weight loss

Serious or Rare Side Effects

  • Severe depression or suicidal thoughts
  • Acute pancreatitis
  • Significant elevation of liver enzymes
  • Peripheral neuropathy

Precautions & Warnings

When prescribing Miglustat, clinicians should consider several safety precautions to minimize risk.

  • Monitor liver function: obtain baseline and periodic liver enzyme tests.
  • Assess mental health: watch for signs of depression or suicidal ideation.
  • Evaluate pancreatic status: monitor for persistent abdominal pain or pancreatitis.
  • Adjust dose in renal impairment: use caution and consider dose reduction in patients with reduced clearance.
  • Avoid in patients with known hypersensitivity to miglustat or its excipients.
  • Store at ambient temperature below 25°C: keep in the original packaging, protect from moisture.

Avoid Interactions

Miglustat can interact with other medicines, affecting its absorption or increasing toxicity.

Major Interactions (Avoid)

  • Co‑administration with other glucosylceramide synthase inhibitors: may increase risk of overlapping adverse effects.
  • Use with high‑dose vitamin B6 supplements: may diminish miglustat’s therapeutic effect.

Moderate Interactions (Monitor Closely)

  • Antacids containing aluminum or magnesium: may reduce miglustat absorption; separate dosing by at least 2 hours.
  • Oral contraceptives: miglustat may lower efficacy; consider alternative contraception or monitor closely.
  • Warfarin: monitor INR as miglustat may affect anticoagulant control.

Frequently Asked Questions

Miglustat Dipharma is indicated for the management of Gaucher disease type 1 and Niemann‑Pick disease type C. In both conditions it acts as substrate reduction therapy, decreasing the accumulation of glycosphingolipids that drive disease pathology.

Miglustat inhibits the enzyme glucosylceramide synthase, which catalyzes the first step in glycosphingolipid synthesis. By blocking this step, the drug reduces the production of glucosylceramide and downstream lipids, lowering their storage in lysosomes and helping to restore cellular function.

The dosage of Miglustat Dipharma is determined by the prescribing clinician based on the patient’s age, weight, renal function, and specific disease indication. Only a qualified health professional can set the appropriate regimen.

Safety data for miglustat in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the treating physician after a thorough risk‑benefit assessment.

To place an enquiry, submit the required quantity on the Miglustat Dipharma product page at gnhindia.com. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Miglustat offers an oral substrate‑reduction option, whereas enzyme‑replacement therapies are administered intravenously. It can be used when patients are unsuitable for infusion therapy or as an adjunct. The choice depends on disease severity, patient preference, and clinical judgment.

Miglustat Dipharma should be stored at ambient temperature below 25 °C, in its original packaging, protected from moisture and direct sunlight. Do not store in a refrigerator or freezer unless otherwise specified by the manufacturer.

Miglustat Dipharma is taken orally, usually with food to reduce gastrointestinal discomfort. The tablets should be swallowed whole with a glass of water and not crushed or chewed, unless the prescriber provides specific instructions.

Serious risks include severe depression or suicidal thoughts, acute pancreatitis, significant liver enzyme elevations, and peripheral neuropathy. Patients should be monitored regularly for these events, and any concerning symptoms should prompt immediate medical evaluation.

Miglustat is contraindicated in individuals with known hypersensitivity to miglustat or any of its excipients. Caution is also advised for patients with severe renal impairment, uncontrolled psychiatric disorders, or active pancreatitis, as these conditions may increase the risk of adverse effects.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Miglustat

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT